RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret Past Earnings Performance
Past criteria checks 4/6
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret has been growing earnings at an average annual rate of 61.4%, while the Biotechs industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 23.8% per year. RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret's return on equity is 27.4%, and it has net margins of 474.6%.
Key information
61.4%
Earnings growth rate
59.4%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 23.8% |
| Return on equity | 27.4% |
| Net Margin | 474.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 53 | 249 | 27 | 8 |
| 30 Jun 23 | 50 | 320 | 25 | 6 |
| 31 Mar 23 | 58 | 302 | 26 | 8 |
| 31 Dec 22 | 86 | 281 | 28 | 8 |
| 30 Sep 22 | 203 | 223 | 33 | 17 |
| 30 Jun 22 | 299 | 146 | 39 | 18 |
| 31 Mar 22 | 368 | 124 | 41 | 19 |
| 31 Dec 21 | 384 | 114 | 41 | 17 |
| 30 Sep 21 | 373 | 113 | 40 | 9 |
| 30 Jun 21 | 307 | 87 | 35 | 8 |
| 31 Mar 21 | 267 | 76 | 37 | 6 |
| 31 Dec 20 | 230 | 61 | 31 | 5 |
| 30 Sep 20 | 127 | 49 | 20 | 4 |
| 30 Jun 20 | 85 | 34 | 13 | 4 |
| 31 Mar 20 | 34 | 12 | 5 | 4 |
| 31 Dec 19 | 17 | 4 | 5 | 4 |
| 30 Sep 19 | 19 | 7 | 6 | 6 |
| 30 Jun 19 | 19 | 8 | 7 | 5 |
| 31 Mar 19 | 21 | 4 | 7 | 4 |
| 31 Dec 18 | 20 | 2 | 7 | 4 |
| 30 Sep 18 | 24 | 2 | 7 | 2 |
| 30 Jun 18 | 29 | 2 | 7 | 3 |
| 31 Mar 18 | 35 | 3 | 7 | 3 |
| 31 Dec 17 | 38 | 4 | 7 | 3 |
| 30 Sep 17 | 38 | 5 | 8 | 2 |
| 30 Jun 17 | 36 | 3 | 8 | 2 |
| 31 Mar 17 | 33 | 3 | 8 | 2 |
| 31 Dec 16 | 32 | 4 | 8 | 2 |
| 30 Sep 16 | 31 | 4 | 8 | 2 |
| 30 Jun 16 | 33 | 6 | 8 | 2 |
| 31 Mar 16 | 34 | 7 | 6 | 2 |
| 31 Dec 15 | 34 | 7 | 7 | 2 |
| 30 Sep 15 | 31 | 7 | 7 | 2 |
| 30 Jun 15 | 31 | 6 | 8 | 1 |
| 31 Mar 15 | 28 | 5 | 7 | 1 |
| 31 Dec 14 | 26 | 5 | 6 | 1 |
| 30 Sep 14 | 24 | 4 | 5 | 1 |
| 30 Jun 14 | 21 | 5 | 3 | 1 |
| 31 Mar 14 | 20 | 5 | 3 | 1 |
| 31 Dec 13 | 19 | 4 | 3 | 1 |
Quality Earnings: RTALB has a high level of non-cash earnings.
Growing Profit Margin: RTALB's current net profit margins are higher than last year .
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RTALB's earnings have grown significantly by 61.4% per year over the past 5 years.
Accelerating Growth: RTALB's earnings growth over the past year (12%) is below its 5-year average (61.4% per year).
Earnings vs Industry: RTALB earnings growth over the past year (12%) exceeded the Biotechs industry -2.9%.
Return on Equity
High ROE: RTALB's Return on Equity (27.4%) is considered high.